Elotuzumab

Summary

Elotuzumab (CHEMBL1743010) is an approved antibody (ATC L01FX08) targeting SLAMF7; indicated across 7 conditions including plasma cell myeloma and neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: L01FX08
• Targets: 1 (SLAMF7)
• Indications: 7 conditions
• Clinical trials: 66

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743010
Name	Elotuzumab
Type	Antibody
Max phase	4
ATC	L01FX08

Also known as: BMS-901608, Elotuzumab, Empliciti, HULUC63, PDL-063, PDL063, ELOTUZUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SLAMF7	CS1 (CD319)	Binding	8.05	0.2%	Q9NQ25

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): SLAMF7.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Adaptive Immune System	1	SLAMF7
Immune System	1	SLAMF7
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	1	SLAMF7

Dominant GO biological processes

GO term	Targets
adaptive immune response	1
immune response	1
cell adhesion	1
natural killer cell activation	1
T cell activation	1
natural killer cell mediated cytotoxicity	1
immune system process	1
innate immune response	1

Indications & clinical

Indications

7 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
plasma cell myeloma	4	MONDO:0009693	EFO:0001378
neoplasm	4	MONDO:0005070	EFO:0000616
smoldering plasma cell myeloma	2	MONDO:0005235	EFO:0003073
plasma cell leukemia	2	MONDO:0018689	EFO:0006475
hematopoietic and lymphoid system neoplasm	2	MONDO:0002334	MONDO:0044881
hereditary amyloidosis	2	MONDO:0018634	MONDO:0019438

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 66.

Phase distribution

Phase	Trials
PHASE2	32
PHASE3	15
PHASE1	8
PHASE1/PHASE2	7
Not specified	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03651128	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
NCT03948035	PHASE3	ACTIVE_NOT_RECRUITING	Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
NCT05028348	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05730036	PHASE3	RECRUITING	A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT06152575	PHASE3	RECRUITING	MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06158841	PHASE3	RECRUITING	Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06208150	PHASE3	RECRUITING	A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT07555938	PHASE3	RECRUITING	Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT01239797	PHASE3	COMPLETED	Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01335399	PHASE3	COMPLETED	Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
NCT01891643	PHASE3	TERMINATED	PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
NCT02495922	PHASE3	COMPLETED	A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
NCT02726581	PHASE3	COMPLETED	An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
NCT05675319	PHASE3	TERMINATED	Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
NCT06232707	PHASE3	WITHDRAWN	A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT02343042	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Selinexor and Backbone Treatments of Multiple Myeloma Patients
NCT02420860	PHASE2	ACTIVE_NOT_RECRUITING	Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT02718833	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
NCT03030261	PHASE2	ACTIVE_NOT_RECRUITING	Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
NCT03989414	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
NCT04517851	PHASE2	ACTIVE_NOT_RECRUITING	Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
NCT04835129	PHASE2	ACTIVE_NOT_RECRUITING	Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT05002816	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
NCT06518551	PHASE1/PHASE2	RECRUITING	Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
NCT06785415	PHASE1/PHASE2	RECRUITING	Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
NCT00742560	PHASE2	COMPLETED	A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
NCT01441973	PHASE2	COMPLETED	Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
NCT01478048	PHASE2	COMPLETED	Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01632150	PHASE2	COMPLETED	Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT01668719	PHASE1/PHASE2	COMPLETED	S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
NCT01729091	PHASE2	COMPLETED	Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT02159365	PHASE2	COMPLETED	Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
NCT02272803	PHASE2	COMPLETED	Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan
NCT02279394	PHASE2	COMPLETED	E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
NCT02375555	PHASE2	COMPLETED	Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
NCT02612779	PHASE2	COMPLETED	A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
NCT02654132	PHASE2	COMPLETED	An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
NCT02719613	PHASE2	COMPLETED	Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
NCT02843074	PHASE2	COMPLETED	Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
NCT02969837	PHASE2	COMPLETED	Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).